|Chemical and physical data|
|Molar mass||377.83 g·mol−1|
|3D model (JSmol)|
Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed.
- Encyclopedia of Psychopharmacology. Springer Science & Business Media. 31 July 2010. pp. 514–. ISBN 978-3-540-68698-9. https://books.google.com/books?id=qoyYobgX0uwC&pg=PA514.
- Innovative Drug Development for Headache Disorders. Oxford University Press. 21 August 2008. pp. 188–. ISBN 978-0-19-955276-4. https://books.google.com/books?id=h72Zdp1gtXYC&pg=PA188.
- Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. 31 August 2012. pp. 1031–. ISBN 978-1-4557-3767-3. https://books.google.com/books?id=R4ATV-17cv8C&pg=PA1031.
Original source: https://en.wikipedia.org/wiki/Dasolampanel. Read more